CDRH's Total Product Life Cycle Advisory Program — TAP — is the kind of thing that gets pitched internally as a fast lane: a dedicated FDA advisor, engaged across your device's whole life cycle, inside a pilot FDA keeps expanding. All of that is true. It is also a voluntary pilot, established by Federal Register notice on October 12, 2022 under the MDUFA V commitment letter, with a fixed annual enrollment cap and an eligibility gate that sits upstream of the application — not inside it.
What TAP actually is
TAP is not a new review pathway alongside the 510(k), De Novo, or PMA — it runs underneath whichever of those a device already uses. What it adds is a dedicated FDA advisor assigned to the sponsor for engagement across the product's total life cycle, intended to make early, iterative interaction with FDA more structured than the episodic Q-Submission meetings most sponsors already use. The commitment letter is explicit that TAP does not change FDA's review standards and that enrollment carries no authorization guarantee — the advisor changes how you reach the agency, not what the agency requires to clear, grant, or approve the device.
The gate before the gate: eligibility and the annual cap
Two separate constraints determine whether a device gets into TAP, and sponsors routinely conflate them. The first is eligibility: through fiscal year 2025, a device needed a granted Breakthrough Device designation to apply at all. Starting in fiscal year 2026, the MDUFA V commitment letter extends that gate to devices with a request for inclusion in the Safer Technologies Program as well — widening the pool, but still requiring the underlying designation decision to be made, and made correctly, before a TAP application is even possible.
- Eligibility gate. A granted Breakthrough designation (all years), or from FY2026 a STeP inclusion request — TAP is downstream of that decision, not a substitute for it.
- Annual cap. The commitment letter ramps enrollment capacity by fiscal year — starting at 15 devices in FY2023 and rising toward an eventual ceiling of at least 325 through FY2027.
- First-come, first-served. Enrollment within a given fiscal year's cap is granted in the order applications are accepted, not by designation priority.
- One product per sponsor, per fiscal year. A sponsor with several eligible devices in the pipeline still gets only one enrollment slot per year and has to choose.
TAP doesn't reward the strongest device. It rewards the sponsor who already had the designation lined up and applied before the fiscal year's capacity ran out. Why timing beats eligibility
What this means for portfolio planning
The one-product-per-fiscal-year limit turns TAP into a portfolio decision, not an application-form decision. A sponsor running two or three Breakthrough-eligible or STeP-eligible programs at once has to decide, before applying, which one gets the fiscal year's single TAP slot — and that decision is easiest to make well before the designation itself is finalized, as part of the same regulatory strategy conversation that sets the Data Development Plan and sprint-meeting cadence a Breakthrough designation already carries. Waiting until after designation is granted to think about TAP means making the portfolio call under time pressure, against a cap that may already be close to full for the year.
- Decide the designation path early. Breakthrough or STeP eligibility has to exist before a TAP application can be filed at all.
- Apply as early in the fiscal year as the designation allows. The cap is first-come-first-served, not merit-ranked.
- Choose the one product that gets the year's slot, deliberately. Don't let a multi-device pipeline default this decision by whichever program happens to clear designation first.
- Build the advisor relationship as an ongoing engagement, not a single meeting. TAP's value compounds across the product's life cycle if the sponsor treats it that way.
None of this makes TAP less valuable — a dedicated advisor across the life cycle of a novel device is a real structural advantage over ad hoc Q-Submissions. It does mean the advantage goes to sponsors who treat designation strategy, application timing, and portfolio prioritization as one sequence rather than three separate decisions made by three different teams on three different schedules.
Frequently asked questions
What devices are eligible for FDA's TAP Pilot?
Through fiscal year 2025, only devices with a granted Breakthrough Device designation were eligible. Starting in fiscal year 2026, the MDUFA V commitment letter extends eligibility to devices with a request for inclusion in the Safer Technologies Program (STeP) as well.
Does TAP enrollment guarantee FDA authorization?
No. TAP assigns an enrolled sponsor a dedicated FDA advisor across the product's total life cycle, but it does not change FDA's review standards, and enrollment is not a guarantee of 510(k) clearance, De Novo grant, or PMA approval.
Is there a limit on how many products TAP will enroll?
Yes. The MDUFA V commitment letter sets a fiscal-year enrollment ceiling that ramps over time — starting at 15 devices in fiscal year 2023 and rising toward at least 325 through fiscal year 2027 — and enrollment within each year's cap is first-come, first-served. Each sponsor may enroll at most one product per fiscal year.
Sources & further reading
- FDA. Medical Devices; Voluntary Total Product Life Cycle Advisory Program Pilot (Federal Register notice, October 12, 2022). federalregister.gov
- FDA. Total Product Life Cycle Advisory Program (TAP) — overview. fda.gov
- FDA. MDUFA Performance Goals and Procedures, Fiscal Years 2023 Through 2027 (MDUFA V commitment letter), Section J.3. fda.gov
This article is provided for general informational purposes and reflects the regulatory landscape as of November 2026. It is not legal or regulatory advice. Confirm current TAP Pilot eligibility criteria, fiscal-year enrollment capacity, and application procedures with FDA before relying on a specific enrollment determination.